<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370772</url>
  </required_header>
  <id_info>
    <org_study_id>CLL 2010 FMP</org_study_id>
    <nct_id>NCT01370772</nct_id>
  </id_info>
  <brief_title>Intensified Rituimab Prephase Before FCR in Untreated B-CLL</brief_title>
  <official_title>Phase II Multicentric, Randomized Trial, Exploring Intensified Rituximab Prephase Monotherapy Before Standard Fludarabine-Cyclophosphamide-Rituximab Regimen in Previously Untreated Symptomatic B-cell Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, multicenter, randomized trial, exploring intensified Rituximab prephase monotherapy
      before standard Fludarabine-Cyclophosphamide-Rituximab FC-R regimen in previously untreated
      symptomatic B-cell chronic lymphocytic leukemia CLL.

      A Study from the Goelams GCFLLCMW intergroup
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Young fit medically B Cell untreated patients Comparison between FCR treatment = 6 FCR cycles
      and a the addition of a prephase with R Dense treatment before the 6 FCR cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rates according to IWCLL 2008 guidelines with undetectable minimal residual disease</measure>
    <time_frame>9 months</time_frame>
    <description>CR MRD negative rate at 9 months = treatment evaluation surveillance of cumulative toxicities of high dose rituximab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine and compare the progression free survival PFS</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate the immunophenotypic response rate after high dose Rituximab alone prephase in DenseR-FC</measure>
    <time_frame>9 months</time_frame>
    <description>Treatment evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate FcyRs polymorphisms influence on clinical response</measure>
    <time_frame>9 months</time_frame>
    <description>R Dense arm treatment evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetics of rituximab and determine the PK-PD relationship of rituximab based on biomarkers.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety profile of higher doses of rituximab</measure>
    <time_frame>41</time_frame>
    <description>5 months treatment and 36 months follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the event-free survival EFS</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine and compare the disease-free survival DFS</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the overall survival OS</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to next treatment TTNT</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia CLL</condition>
  <arm_group>
    <arm_group_label>Standard R-FC arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard R-FC arm 6 cycles every 28 days
Cycle 1:
Rituximab : 375 mg/m² i.v on day 1
Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days
Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days For patients with Leucocyte count &gt; 25* G/L : rituximab in two equal doses at D1, D2
Cycle 2-6:
Rituximab: 500 mg/m² i.v on day 1, repeated every 28 days
Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days
Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DenseR-FC arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DenseR-FC arm =1 prephase R Dense course +6 R-FC courses
Prephase:
- Rituximab: 500 mg on day 0, 2000 mg on days 1, 8, and D15 For patients with Leucocyte count &gt; 25* G/L : rituximab 250 mg D-1, D0 prephase
Cycle 1-6 (cycle 1 beginning at D22):
Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days
Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days
Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Cycle 1 Rituximab : 375 mg/m² i.v on day 1
Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days</description>
    <arm_group_label>Standard R-FC arm</arm_group_label>
    <other_name>R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15
Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days</description>
    <arm_group_label>DenseR-FC arm</arm_group_label>
    <other_name>R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days</description>
    <arm_group_label>Standard R-FC arm</arm_group_label>
    <arm_group_label>DenseR-FC arm</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days</description>
    <arm_group_label>Standard R-FC arm</arm_group_label>
    <arm_group_label>DenseR-FC arm</arm_group_label>
    <other_name>F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient information and written informed consent

          -  18 years &lt; Age &lt; 66 ans

          -  confirmed B-CLL Matutes score 4 or 5

          -  Binet stage C or Binet stage A and B with active disease could be considered for
             inclusion. For stage A with active disease an agreement of investigator coordinator is
             required.

          -  no prior treatment except steroids for less than 1 month (detail corticoid)

          -  No 17p deletion as assessed by FISH &lt; 10 % positive nuclei

          -  Performance status ECOG &lt; 2

          -  CIRS Cumulative Illness Rating Scale &lt; 6

        Exclusion criteria:

          -  Binet stage A without active disease according to IWCLL 2008 criteria

          -  Know HIV seropositivity

          -  Hepatitis B or C seropositivity unless clearly due to vaccination

          -  Life expectancy &lt; 6 months

          -  Clinically significant auto-immune anemia

          -  Active second malignancy currently requiring treatment (except basal cell carcinoma in
             situ endometrial carcinoma and incidental prostate carcinoma) and/or less than 5 years
             CR after breast cancer

          -  Any severe co-morbid conditions such as Class III or IV heart failure, myocardial
             infarction within 6 months, unstable angina, ventricular tachyarythmias requiring
             ongoing treatment, severe chronic obstructive pulmonary disease with hypoxemia,
             uncontrolled diabetes mellitus, or uncontrolled hypertension

          -  Concomitant disease requiring prolonged use of corticosteroids &gt; 1 month

          -  Known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies
             or any of the study drugs According to the SmPC or investigator practice

          -  Contraindication to use of Rituximab

          -  Transformation to aggressive B-cell malignancy e.g. diffuse large cell lymphoma,
             Hodgkin lymphoma, or prolymphocytic leukaemia

          -  Active bacterial, viral or fungal infection

          -  Abnormal renal function with creatinine clearance &lt; 60 ml/min calculated according to
             the Cockcroft and Gault formula

          -  Total bilirubin, gamma glutamyltransferase or transaminase levels &gt; 2.5 ULN.

          -  Any coexisting medical or psychological condition that would preclude participation in
             the required study procedures

          -  Patient with mental deficiency preventing proper understanding of the requirements of
             treatment.

          -  Pregnant or breastfeeding women.

          -  Adult under law-control

          -  Fertile male and female patients who cannot or do not wish to use an effective method
             of contraception, during and for 12 months after the final treatment used for the
             purposes of the study.

          -  No afiliate to social security
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume CARTRON, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephane LEPRETRE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stephane LEPRETRE</name>
      <address>
        <city>Rouen</city>
        <state>CLCC Henri Becquerel</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guillaume CARTRON</name>
      <address>
        <city>Montpellier</city>
        <state>Regional university Hospital</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO Website</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B CLL</keyword>
  <keyword>Fist line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

